Switching the Histamine H2 Receptor Antagonist Famotidine to Nonprescription Status in Canada: An Economic Evaluation

PharmacoEconomics

Volumn 9, Issue 1, 1996, Pages 61-75

  Tasch, Rachel F ^a,e   Goeree, Ron ^b,c   Henke, Curtis J ^a,d   O'Brien, Bernie J ^b,c  

^a Technology Assessment Group   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Technology Assessment Group   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; NON PRESCRIPTION DRUG;

ARTICLE; CANADA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DECISION THEORY; DYSPEPSIA; HEALTH CARE; HEARTBURN; HUMAN; PHARMACY; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; SELF MEDICATION; SOCIETY; DECISION SUPPORT SYSTEM; ECONOMICS; TREATMENT OUTCOME;

CANADA; DECISION SUPPORT TECHNIQUES; DRUGS, NON-PRESCRIPTION; FAMOTIDINE; HEARTBURN; HISTAMINE H2 ANTAGONISTS; HUMANS; TREATMENT OUTCOME;

EID: 0029666452     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199609010-00007     Document Type: Review

References (43)

1. Tasch RF, Fenton A. Incidence of common gastrointestinal complaints and patient treatment patterns in Canada [abstract]. Pharmacoepidemiol Drug Saf 1995; 4 Suppl. 1: S51
2. Cranz H. Over-the-counter drugs: the issues. Drug Saf 1990; 5 Suppl. 1: 120-5
3. IMS Canada. Canadian disease and therapeutic index. Mississauga (Ont.): IMS Canada, 1993
4. Brogan Consulting Services. Manufacturer's report. Ottawa: Brogan Consulting, 1993
5. MacIsaac W, Naylor CD, Anderson GM, et al. Reflections on a month in the life of the Ontario Drug Benefit Plan. Can Med Assoc J 1994; 150: 473-7
6. Canadian Pharmaceutical Association. Compendium of pharmaceuticals and specialties. 13th ed. Ottawa: Canadian Pharmaceutical Association, 1995
7. Klein & Company. Nonprescription drugs: Canada, 1992. Fairfield (NJ): Klein & Company Inc., 1992: 4-52
8. 2-antagonists. Drug Saf 1993; 8 (3): 179-85
9. 2-receptor antagonists in Denmark before and after transfer of cimetidine and ranitidine to over-the-counter status. Pharmacol Toxicol 1991; 69: 253-8
10. Feldman M. Pros and cons of over-the-counter availability of histamine2-receptor antagonists. Arch Intern Med 1993; 153: 2215-24
11. 2-blockers. Med Care 1990; 28: 834-52
12. Simon TJ, Gardner AH, Stauffer LA, et al. Self-directed treatment of intermittent heartburn: a randomized, multicenter, double-blind, placebo-controlled evaluation of famotidine 5, 10 & 20 mg and antacid [abstract]. Gastroenterology 1994; 106(4): A161
13. Andersson F, Hatziandreu E. The costs and benefits of switching a drug from prescription-only to over-the-counter status: a review of methodological issues and current evidence. PharmacoEconomics 1992; 2 (5): 388-96
14. Chiba N, de Gara CJ, Burget DW, et al. Rapidity of healing in GERD: a comparison of different drug classes by meta-analysis [abstract]. Gastroenterology 1993; 104 Suppl.: A53
15. 2-receptor antagonists: how will they affect the treatment of acid-related diseases? Drugs 1994; 47 (1): 1-11
16. Johnson DA. Medical therapy for gastroesophageal reflux disease. Am J Med 1992; 92 Suppl. 5A: 88S-97S
17. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15
18. Mohamed AH, Chiba N, Wilkinson J, et al. Long-term management of reflux esophagitis (grade II-IV) with ranitidine or omeprazole [abstract]. Gastroenterology 1994; 106(4): A171
19. Talley NJ, Zinsmeister AR, Schleck CD, et al. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992; 102: 1259-68
20. Talley NJ, Phillips SF. Non-ulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988; 108: 865-79
21. 2-antagonists for the relief of dyspepsia. Pharm J 1994; 252: 84-8
22. Zell SC, Budhraja M. An approach to dyspepsia in the ambulatory care setting: evaluation based on risk stratification. J Gen Intern Med 1989; 4: 144-50
23. Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985; 37 (5): 980-91
24. Talley NJ, McNeil D, Hayden A, et al. Randomized, double-blind, placebo controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986; 91: 149-56
25. Saunders JHB, Oliver RJ, Higson DL. Dyspepsia: incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. BMJ 1986; 292: 665-8
26. Johannesson T, Fjosns U, Kleveland PM, et al. Cimetidine responders in non-ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 327-36
27. Kleveland PM, Larsen S, Sandvik L, et al. The effects of cimetidine in non-ulcer dyspepsia: experience with a multi-crossover model. Scand J Gastroenterol 1985; 20: 19-24
28. Farup PG, Larsen S, Ulshagen K, et al. Ranitidine for non-ulcer dyspepsia: a clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991; 26: 1209-16
29. Robinson M, Decktor DL, Stone RC, et al. Famotidine (20 mg) b.d. relieves gastro-oesophageal reflux symptoms in patients without erosive oesophagitis. Aliment Pharmacol Ther 1991; 5: 631-43
30. Wesdorp ICE. Famotidine in gastroesophageal reflux disease (GERD). Hepatogastroenterology 1992; 39 Suppl. I: 24-6
31. Sabesin SM, Berlin RG, Humphries TJ, et al. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Arch Intern Med 1991; 151: 2394-400
32. Simon TJ, Berlin RG, Tipping R, et al. Efficacy of twice daily doses of 40 or 20 milligrams famotidine or 150 milligrams ranitidine for treatment of patients with moderate to severe erosive esophagitis. Scand J Gastroenterol 1993; 28: 375-80
33. Korn SH, Vassil TC, Raskin SJ, et al Usage trial of famotidine [abstract]. Meetings of the American Gastroenterology Association. American Association for the Study of Liver Disease (AASLD) at Digestive Disease Week; 1995 May 14-17: San Diego. Gastroenterology 1995; 108 (4 Suppl.): A135
34. Nielsen Marketing Research. September-October rolling annual total, 1993. Markham (Ont.): A.C. Nielsen Inc., 1993
35. Ontario Ministry of Health. Drug benefit formulary: comparative drug index. Toronto: Publications Ontario, 1994
36. Ontario Ministry of Health. Schedule of benefits: physician services under the Health Insurance Act. Toronto: Publications Ontario, 1993
37. Centre for Health Economics and Policy Analysis. Chedoke/ McMaster University hospital costing model. Hamilton (Ont.): McMaster University, 1994
38. Peck C, Coleman G. Implications of placebo theory for clinical research and practice in pain management. Theor Med 1991 Sep; 12 (3): 247-70
39. Remington G, Fornazzari L, Sethna R. Placebo response in refractory tardive akathisia. Can J Psychiatry 1993; 38: 248-50
40. Wall PD. Pain and the placebo response. In: Experimental and theoretical studies of consciousness. Ciba Found Symp 1993; 174: 187-216
41. Schumacher MC, Jick SS, Feld AD. Cimetidine use and gastric cancer. Epidemiology 1990; 1: 251-4
42. Walt RP, Webberley MJ. The safety profile of famotidine. Rev Contemp Pharmacother 1992; 3: 405-13
43. Mikulin T, Hardcastle JD. Gastric cancer - delay in diagnosis and its causes. Eur J Gastroenterol Clin Oncol 1987; 23 (11): 1683-90